Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.

Grundschober E, Hoelbl-Kovacic A, Bhagwat N, Kovacic B, Scheicher R, Eckelhart E, Kollmann K, Keller M, Grebien F, Wagner KU, Levine RL, Sexl V.

Leukemia. 2014 Sep;28(9):1918-22. doi: 10.1038/leu.2014.152. Epub 2014 May 5. No abstract available.

2.

Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance.

Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, Gotthardt D, Warsch W, Eckelhart E, Kantner HP, Kalinke U, Lienenklaus S, Weiss S, Strobl B, Müller M, Sexl V, Stoiber D.

Oncoimmunology. 2012 Oct 1;1(7):1027-1037.

3.

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.

Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU, Superti-Furga G, Sexl V.

Nat Chem Biol. 2012 Jan 29;8(3):285-93. doi: 10.1038/nchembio.775.

PMID:
22286129
4.

c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6.

Kollmann K, Heller G, Ott RG, Scheicher R, Zebedin-Brandl E, Schneckenleithner C, Simma O, Warsch W, Eckelhart E, Hoelbl A, Bilban M, Zöchbauer-Müller S, Malumbres M, Sexl V.

Blood. 2011 Apr 14;117(15):4065-75. doi: 10.1182/blood-2010-07-299644. Epub 2011 Feb 7.

PMID:
21300982
5.

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, Herrmann H, Sillaber C, Egger G, Valent P, Moriggl R, Sexl V.

Blood. 2011 Mar 24;117(12):3409-20. doi: 10.1182/blood-2009-10-248211. Epub 2011 Jan 10.

PMID:
21220747
6.

A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development.

Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, Kolbe T, Rülicke T, Mueller M, Casanova E, Sexl V.

Blood. 2011 Feb 3;117(5):1565-73. doi: 10.1182/blood-2010-06-291633. Epub 2010 Dec 2.

PMID:
21127177
7.

Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer.

El-Gazzar A, Perco P, Eckelhart E, Anees M, Sexl V, Mayer B, Liu Y, Mikulits W, Horvat R, Pangerl T, Zheng D, Krainer M.

Mol Cancer Ther. 2010 Apr;9(4):1007-18. doi: 10.1158/1535-7163.MCT-09-0933. Epub 2010 Apr 6.

8.

The protein tyrosine kinase Tec regulates mast cell function.

Schmidt U, Abramova A, Boucheron N, Eckelhart E, Schebesta A, Bilic I, Kneidinger M, Unger B, Hammer M, Sibilia M, Valent P, Ellmeier W.

Eur J Immunol. 2009 Nov;39(11):3228-38. doi: 10.1002/eji.200838839.

9.

Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance.

Zebedin E, Simma O, Schuster C, Putz EM, Fajmann S, Warsch W, Eckelhart E, Stoiber D, Weisz E, Schmid JA, Pickl WF, Baumgartner C, Valent P, Piekorz RP, Freissmuth M, Sexl V.

Blood. 2008 Dec 1;112(12):4655-64. doi: 10.1182/blood-2008-02-139105. Epub 2008 Aug 6.

PMID:
18684865

Supplemental Content

Loading ...
Support Center